Effect of moxonidine on the uveoscleral outflow: role of alpha2-adrenoceptors or i1 imidazoline receptors.
OBJECTIVE
The purpose of this study is to assess the change of uveoscleral outflow induced by moxonidine and to investigate whether the increase of uveoscleral outflow induced by moxonidine is mediated by alpha1, alpha2, or I1 receptors.


METHODS
0.05% moxonidine was topically and unilaterally administered in rabbit eyes with or without pretreatment of prazosin, yohimbine, efaroxan, or AGN 192403, as indicated. We injected fluorescein isothiocyanate-bovine serum albumin (FITC-BSA) into the anterior chamber and observed the fluorescence intensity of the uveoscleral outflow. Finally, the volume of uveoscleral outflow was calculated based on the fluorescence intensities captured.


RESULTS
A bilateral increase of fluorescence intensity was observed along the uveoscleral outflow pathway following moxonidine administration, especially in the ciliary body and supraciliochoroidal space. Pretreatment with prazosin further enhanced the bilateral increase of fluorescence intensity at between 2 and 4 hours after moxonidine administration. The response of moxonidine was antagonized by either yohimbine, an alpha2 receptor antagonist, or efaroxan, an I1/alpha2 receptor antagonist. The antagonizing effect of yohimbine was more potent than that of efaroxan. The moxonidne-induced response was not antagonized by AGN 192403, an I1 receptor antagonist. The bilateral volumes of aqueous humor within the uveoscleral pathway increased significantly induced by moxonidine (p < 0.01 versus control). The increased bilateral volumes of uveoscleral outflow were 0.381 +/- 0.073 and 0.376 +/- 0.095 mu l/min, respectively.


CONCLUSIONS
These results suggest that topical, unilateral administration of moxonidine causes a bilateral increase of aqueous humor via the uveoscleral outflow pathway. The moxonidine-induced increase of uveoscleral outflow is mediated by alpha2 adrenergic receptors, not by I1 imidazoline receptors.
Yang
Jiangang
J
Department of Ophthalmology, Second Affiliated Hospital of Medical School, Xi'an Jiaotong University, Xi'an, China.
Sun
Naixue
N
Xiong
Quanchen
Q
Yang
Rui
R
D000287:Administration, Topical; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D001082:Aqueous Humor / Q000187:drug effects / Q000378:metabolism*; D001572:Benzofurans / Q000494:pharmacology; D001643:Bridged Bicyclo Compounds / Q000494:pharmacology; D004357:Drug Synergism; D016650:Fluorescein-5-isothiocyanate / Q000031:analogs & derivatives; D006536:Heptanes / Q000494:pharmacology; D007093:Imidazoles / Q000008:administration & dosage / Q000494:pharmacology*; D054755:Imidazoline Receptors / Q000037:antagonists & inhibitors / Q000378:metabolism*; D011224:Prazosin / Q000494:pharmacology; D011817:Rabbits; D018341:Receptors, Adrenergic, alpha-2 / Q000378:metabolism*; D012590:Sclera / Q000187:drug effects / Q000378:metabolism*; D012710:Serum Albumin, Bovine; D014602:Uvea / Q000187:drug effects / Q000378:metabolism*; D015016:Yohimbine / Q000494:pharmacology
C098523:AGN 192403; D000317:Adrenergic alpha-Antagonists; D001572:Benzofurans; D001643:Bridged Bicyclo Compounds; D006536:Heptanes; D007093:Imidazoles; D054755:Imidazoline Receptors; D018341:Receptors, Adrenergic, alpha-2; C039217:fluorescein isothiocyanate bovine serum albumin; C410887:imidazoline I1 receptors; D012710:Serum Albumin, Bovine; D015016:Yohimbine; C043482:moxonidine; C062597:efaroxan; D016650:Fluorescein-5-isothiocyanate; D011224:Prazosin